Key Insights

Highlights

Success Rate

91% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 15/100

Termination Rate

4.3%

1 terminated out of 23 trials

Success Rate

90.9%

+4.4% vs benchmark

Late-Stage Pipeline

17%

4 trials in Phase 3/4

Results Transparency

70%

7 of 10 completed with results

Key Signals

7 with results91% success

Data Visualizations

Phase Distribution

19Total
Not Applicable (2)
Early P 1 (2)
P 1 (4)
P 2 (7)
P 3 (1)
P 4 (3)

Trial Status

Completed10
Recruiting5
Unknown4
Withdrawn2
Active Not Recruiting1
Terminated1

Trial Success Rate

90.9%

Benchmark: 86.5%

Based on 10 completed trials

Clinical Trials (23)

Showing 20 of 20 trials
NCT02632344Phase 2CompletedPrimary

Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients

NCT04645602Early Phase 1Recruiting

Merck IIT: RRP Pembro and Lenvatinib

NCT07317154Phase 1RecruitingPrimary

Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) Patients

NCT06538480Phase 4RecruitingPrimary

Zopa Retreatment and Vector Shedding in Adults With RRP

NCT06412172RecruitingPrimary

The Natural History and Biological Study of Pulmonary Recurrent Respiratory Papillomatosis (pRRP)

NCT04724980Phase 1Active Not RecruitingPrimary

Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis

NCT01793168Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

NCT03707587Phase 2CompletedPrimary

M7824 in People With Recurrent Respiratory Papillomatosis

NCT03465280UnknownPrimary

Airway Intervention Registry (AIR): Recurrent Respiratory Papillomatosis (RRP)

NCT02859454Phase 2CompletedPrimary

Avelumab for People With Recurrent Respiratory Papillomatosis

NCT00205374Phase 4CompletedPrimary

Use of Cidofovir for Recurrent Respiratory Papillomatosis

NCT02592902Not ApplicableCompletedPrimary

Recurrent Respiratory Papillomatosis and Extraesophageal Reflux

NCT00571701Phase 2CompletedPrimary

Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis

NCT00829608Early Phase 1WithdrawnPrimary

Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis

NCT02217358Not ApplicableCompleted

Value of Narrow Band Imaging (NBI) Endoscopy in the Early Diagnosis of Laryngeal Cancer and Precancerous Lesions

NCT02854761Phase 1UnknownPrimary

Safety Study of EF-022 in Adults With Recurrent Respiratory Papillomatosis (RRP)

NCT02555800Phase 2UnknownPrimary

Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis

NCT00747461Phase 4Terminated

Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")

NCT01995721Phase 3UnknownPrimary

4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children

NCT01058317Phase 2WithdrawnPrimary

Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis

Scroll to load more

Research Network

Activity Timeline